ArticleStem cell reviews and reports2012
Highly efficient zinc-finger nuclease-mediated disruption of an eGFP transgene in keratinocyte stem cells without impairment of stem cell properties.
Article in Stem cell reviews and reports, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Risk associated with off-target plant genome editing and methods for its limitation.Emerging topics in life sciences · 2017Article
- Traceless Targeting and Isolation of Gene-Edited Immortalized Keratinocytes from Epidermolysis Bullosa Simplex Patients.Molecular therapy. Methods & clinical development · 2017Article
- Genome editing technologies: defining a path to clinic.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Non-integrating gamma-retroviral vectors as a versatile tool for transient zinc-finger nuclease delivery.Scientific reports · 2014Article
- Efficient designer nuclease-based homologous recombination enables direct PCR screening for footprintless targeted human pluripotent stem cells.Stem cell reports · 2014Article
- Histone deacetylase inhibition rescues gene knockout levels achieved with integrase-defective lentiviral vectors encoding zinc-finger nucleases.Human gene therapy methods · 2013Article
- Versatile and efficient genome editing in human cells by combining zinc-finger nucleases with adeno-associated viral vectors.Human gene therapy · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Zinc-finger nucleases (ZFNs) are sequence-specific genome engineering tools with great potential for the development of gene therapies. The achievement of permanent cures through gene therapy requires targeting of stem cells but the effects and/or side effects of ZFN treatment on adult stem cell potency are largely unknown. Keratinocyte stem cells (KSCs) are attractive candidates for the development of gene therapies as their isolation, culture and grafting are well established. We derived KSCs from eGFP-transgenic mice and knocked out eGFP expression by disrupting the open reading frame with specific ZFNs in cell culture. EGFP-negative KSCs were then used as a model system to study the impact of ZFN treatment on stem cell potential. We achieved high gene disruption efficiencies with up to 18% eGFP-negative KSCs. As expected, ZFN cytotoxicity increased with rising ZFN concentrations. However, the ratio of correctly targeted KSCs among total treated cells was similar at different ZFN doses. Most importantly, our in vitro assays showed that ZFN-treated KSCs maintained their stem cell potential. They retained the capacity to both self-renew and form fully differentiated epidermal equivalents in culture. Moreover, they were able to form spherical aggregates in suspension culture, a characteristic hallmark shared with other stem cell types, and they expressed the in vivo KSC markers K15, NFATc1 and Sox9. Our data suggest that the stem cell potential of KSCs is not impaired by highly efficient ZFN treatment.
Indexed as
Identifiers
21874280What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.